Background and Objectives Red-blood-cell genotyping is used to provide extended matched blood, resolve typing discrepancies and predict phenotype in recently transfused patients or patients with a positive direct antiglobulin test. The aim of this study was to complete a performance and operational evaluation of a genotyping system, ID CORE XT (Progenika Biopharma-Grifols, Barcelona, Spain), within a hospital transfusion service, using the current genotyping method as a reference for comparison.Materials and Methods DNA was extracted from blood donor and patient samples and tested using ID CORE XT and the reference method. Predicted RBC phenotype, turnaround time and hands-on time were compared. A questionnaire was administered to each clinical laboratory scientist to evaluate each platform's ease of use.Results A total of 438 samples were tested and overall agreement between methods was 99Á99%, with a single M antigen typing discrepancy noted. DNA sequencing revealed that ID CORE XT incorrectly designated the antigen status as M-negative, resulting in a false-negative M antigen predicted phenotype result. ID CORE XT showed a 24Á5% and 51Á3% reduction in mean turnaround time and hands-on time, respectively, as compared to the reference method.Conclusion ID CORE XT and the reference method are highly concordant regarding predicted phenotype. ID CORE XT offers several operational advantages, making it suitable for a busy hospital transfusion service.